Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Björn Stollenwerk, Sergio Iannazzo, Kerry Cooper & Vasily Belozeroff. (2017) Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy. Journal of Medical Economics 20:10, pages 1110-1115.
Read now
Read now
Nigar Sekercioglu, Jason W. Busse, M. Fatih Sekercioglu, Arnav Agarwal, Shaun Shaikh, Luciane Cruz Lopes, Reem A. Mustafa, Gordon H. Guyatt & Lehana Thabane. (2016) Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Renal Failure 38:6, pages 857-874.
Read now
Read now
Valentina Lorenzoni, Leopoldo Trieste & Giuseppe Turchetti. (2015) The cost–effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet. Expert Review of Pharmacoeconomics & Outcomes Research 15:4, pages 611-624.
Read now
Read now
Farhanah Yousaf & Chaim Charytan. (2014) Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. Renal Failure 36:1, pages 131-138.
Read now
Read now
Vasily Belozeroff, Andrew Lee, Spring Tseng, Silvia Chiroli & Jonathan D. Campbell. (2013) Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet. Journal of Medical Economics 16:9, pages 1154-1162.
Read now
Read now
Articles from other publishers (8)
Lin Liu, Dongsheng Hong, Kuifen Ma, Bin Wu & Xiaoyang Lu. (2020) Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial. BMJ Open 10:8, pages e034123.
Crossref
Crossref
Brittany Greene, S. Joseph Kim, Ellen P. McCarthy & Jesse D. Pasternak. (2019) Effects of Social Disparities on Management and Surgical Outcomes for Patients with Secondary Hyperparathyroidism. World Journal of Surgery 44:2, pages 537-543.
Crossref
Crossref
Björn Stollenwerk, Sergio Iannazzo, Ron Akehurst, Michael Adena, Andrew Briggs, Bastian Dehmel, Patrick Parfrey & Vasily Belozeroff. (2018) A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. PharmacoEconomics 36:5, pages 603-612.
Crossref
Crossref
Evan W. Davies, Louis S. Matza, Gavin Worth, David H. Feeny, Jacqueline Kostelec, Steven Soroka, David Mendelssohn, Philip McFarlane & Vasily Belozeroff. (2015) Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. Health and Quality of Life Outcomes 13:1.
Crossref
Crossref
Vasily Belozeroff, Glenn M. Chertow, Christopher N. Graham, Bastian Dehmel, Patrick S. Parfrey & Andrew H. Briggs. (2015) Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value in Health 18:8, pages 1079-1087.
Crossref
Crossref
Amit Sharma, Thomas S. Marshall, Samina S. Khan & Beverly Johns. (2013) Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin?D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA. Clinical Drug Investigation 34:2, pages 107-115.
Crossref
Crossref
Shunsuke Goto, Hirotaka Komaba, Masafumi Fukagawa & Shinichi Nishi. (2013) Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. Kidney International Supplements 3:5, pages 457-461.
Crossref
Crossref
J. Floege & V.M. Brandenburg. (2012) KalzimimetikaCalcimimetics. Der Nephrologe 8:1, pages 56-62.
Crossref
Crossref